Unlocking the Role of OCT4 in Cancer Lineage Plasticity: A Cross-Cancer Perspective with an Emphasis on Prostate Cancer

Unlocking the Role of OCT4 in Cancer Lineage Plasticity: A Cross-Cancer Perspective with an Emphasis on Prostate Cancer

Prostate cancer (PCa) is a highly heterogeneous disease, with castration-resistant prostate cancer (CRPC) and neuroendocrine prostate cancer (NEPC) representing its most aggressive and therapy-resistant forms. Emerging evidence indicates that lineage plasticity—driven by key transcription factors su...

Full description

Saved in:

Bibliographic Details
Main Authors:	Mohammad Esfini Farahani, Yanquan Zhang, Amos Olalekan Akinyemi, Fatemeh Seilani, Md Rakibul Alam, Xiaoqi Liu
Format:	Article
Language:	English
Published:	MDPI AG 2025-07-01
Series:	Biomedicines
Subjects:	octamer-binding transcription factor 4 prostate cancer stem cells androgen deprivation therapy castration-resistant prostate cancer neuroendocrine prostate cancer
Online Access:	https://www.mdpi.com/2227-9059/13/7/1642
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Advancements in Research on Non-AR- Signaling Pathways and Targeted Therapies for Castration-Resistant Prostate Cancer
by: Haq Dad, et al.
Published: (2025-01-01)

Research progress on mechanisms of endocrine therapy resistance in prostate cancer
by: QI Zihao, et al.
Published: (2025-04-01)

Prognostic value of prostate-specific antigen in advanced prostate cancer treated with androgen deprivation therapy and abiraterone
by: L. Lou, et al.
Published: (2024-11-01)

Sideroflexin family genes were dysregulated and associated with tumor progression in prostate cancers
by: Hua Huang, et al.
Published: (2025-02-01)

Outcomes of patients older than 75 years with non-metastatic prostate cancer
by: Yoshiyasu Amiya, et al.
Published: (2017-04-01)

Treatment patterns in hormone-sensitive metastatic prostate cancer: data from a referral hospital in Bogota, real-world evidence study
by: Juliana Arenas-Hoyos, et al.
Published: (2024-07-01)

Wnt5a augments intracellular free cholesterol levels and promotes castration resistance in prostate cancer
by: Yuqi Guo, et al.
Published: (2025-03-01)

Impact of androgen deprivation therapy on cognitive function in men with prostate cancer
by: Yutaka Yamamoto, et al.
Published: (2024-03-01)

Regulation of androgen receptor variants in prostate cancer
by: Yezi Zhu, et al.
Published: (2020-07-01)

Rapid and sustainable deep testosterone reduction predicts effective androgen deprivation therapy for metastatic hormone-sensitive prostate cancer
by: Ze Wang, et al.
Published: (2025-08-01)

A 6-month sustained-release formulation of triptorelin for locally advanced or metastatic prostate cancer: a real-world experience in Asia
by: Chi-Hang Yee, et al.
Published: (2025-02-01)

Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach
by: Almudena Zapatero, et al.
Published: (2025-07-01)

Alteration in expression and subcellular localization of the androgen receptor- regulated FAM111A protease is associated with emergence of castration resistant prostate cancer
by: Maria Malvina Tsamouri, et al.
Published: (2025-08-01)

The correlation between the expression of androgen receptor splice variant-7 (AR-V7) protein with the time of occurrence of castration-resistant prostate cancer and overall survival in prostate cancer in Indonesian population
by: Indrawarman Soerohardjo, et al.
Published: (2025-02-01)

Prostatic duct adenocarcinoma—A challenging variant of prostate cancer in a low‐resource setting
by: Ronald Okidi, et al.
Published: (2024-11-01)

Association between the molecular markers, effect and time of response to the androgen-deprivation therapy in patients with prostate cancer
by: L. V. Spirina, et al.
Published: (2019-04-01)

Dysphasia: metastatic prostate cancer to the leptomeninges: a case report
by: Diana Jodeh, et al.
Published: (2024-10-01)

Androgen receptor as a potential therapeutic target in castration-resistant prostate cancer: a bibliometric analysis (2005–2024)
by: Jiexiang Zhang, et al.
Published: (2025-07-01)

Androgen deprivation therapy and the risk of subsequent keratitis
by: Dai-Wei Liu, et al.
Published: (2021-01-01)

Casting a wide net for anemia in advanced prostate cancer: A case series
by: Aneeqa Zafar, et al.
Published: (2025-09-01)

Analysis of innovative clinical developments in the field of therapy for metastatic prostate cancer: bright results of the ASCO Congress-2022
by: D. A. Andreev, et al.
Published: (2022-06-01)

A Single-Center, Retrospective, Real-World, Observational Clinical Study to Evaluate the Safety and Efficacy of Abiraterone (Abiratred) in Patients with Metastatic Prostate Cancer
by: Pongwut Danchaivijitr, et al.

Androgen receptor inhibitors in treating prostate cancer
by: Ryan N Cole, et al.
Published: (2025-03-01)

Androgens and severity of the new coronavirus infection course
by: A. A. Gritskevich, et al.
Published: (2022-06-01)

A novel lncRNA FLJ promotes castration resistance in prostate cancer through AR mediated autophagy
by: Yingying Wu, et al.
Published: (2025-03-01)

Meta-analyses of mouse and human prostate single-cell transcriptomes reveal widespread epithelial plasticity in tissue regression, regeneration, and cancer
by: Luis Aparicio, et al.
Published: (2025-01-01)

Screening and validation of key genes involved in castration-resistant prostate cancer based on transcriptomics sequencing
by: Guangquan Tong, et al.
Published: (2025-07-01)

Current advances of targeting epigenetic modifications in neuroendocrine prostate cancer
by: Wen-Chi Cheng, et al.
Published: (2021-01-01)

Aberrant expression of multiple γ-glutamyltransferases is associated with tumor progression and patient outcome in prostate cancers
by: Wencong Jiang, et al.
Published: (2025-02-01)

Thrombo-inflammation linking androgen suppression with cardiovascular risk in patients with prostate cancer
by: Antonia Beitzen-Heineke, et al.
Published: (2024-12-01)

Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
by: Alexander W Wyatt, et al.
Published: (2015-04-01)

Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots
by: Per-Anders Abrahamsson
Published: (2017-10-01)

Prognostic Expression Signature of RB1, PTEN, and TP53 Genes in Patients with Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
by: Marta Garcia de Herreros, et al.
Published: (2024-12-01)

Therapy results of patients with metastatic castration‑resistant prostate cancer. Regional experience
by: P. G. Berezin, et al.
Published: (2023-03-01)

Biomarkers and Personalized Medicine in Prostate Cancer – Advent of Precision Oncology in (Radio) Therapy Decision-Making
by: Antonela Njavro, et al.
Published: (2024-01-01)

KAT5 promotes tumor growth in androgen-independent prostate cancer by facilitating aerobic glycolysis
by: Wei He, et al.
Published: (2025-08-01)

Vaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer
by: Robert D. Marek, et al.
Published: (2024-11-01)

Pathologic response as an early endpoint for survival following neoadjuvant androgen deprivation therapy plus abiraterone acetate for metastatic prostate cancer
by: Kaichen Zhou, et al.
Published: (2025-04-01)

Evaluating the Effects of Prostate Radiotherapy Intensified with Pelvic Nodal Radiotherapy and Androgen Deprivation Therapy on Myelosuppression: Single-Institution Experience
by: Yousef Katib, et al.
Published: (2024-09-01)

TAXANES IN THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER
by: T. N. Skvortsova, et al.
Published: (2017-01-01)